uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Effects of Denosumab on Fracture and Bone Mineral Density by Level of Kidney Function
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
Show others and affiliations
2011 (English)In: Journal of Bone and Mineral Research, ISSN 0884-0431, E-ISSN 1523-4681, Vol. 26, no 8, 1829-1835 p.Article in journal (Refereed) Published
Abstract [en]

The incidences of osteoporosis and chronic kidney disease (CKD) both increase with increasing age, yet there is a paucity of data on treatments for osteoporosis in the setting of impaired kidney function. We examined the efficacy and safety of denosumab (DMAb) among subjects participating in the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6Months (FREEDOM) Study. We estimated creatinine clearance (eGFR) using Cockcroft-Gault and classified levels of kidney function using the modified National Kidney Foundation classification of CKD. We examined incident fracture rates; changes in bone mineral density (BMD), serum calcium, and creatinine; and the incidence of adverse events after 36 months of follow-up in subjects receiving DMAb or placebo, stratified by level of kidney function. We used a subgroup interaction term to determine if there were differences in treatment effect by eGFR. Most (93%) women were white, and the mean age was 72.3 +/- 5.2 years; 73 women had an eGFR of 15 to 29mL/min; 2817, between 30 to 59mL/min; 4069, between 60 to 89mL/min, and 842 had an eGFR of 90mL/min or greater. None had stage 5 CKD. Fracture risk reduction and changes in BMD at all sites were in favor of DMAb. The test for treatment by subgroup interaction was not statistically significant, indicating that treatment efficacy did not differ by kidney function. Changes in creatinine and calcium and the incidence of adverse events were similar between groups and did not differ by level of kidney function. It is concluded that DMAb is effective at reducing fracture risk and is not associated with an increase in adverse events among patients with impaired kidney function.

Place, publisher, year, edition, pages
2011. Vol. 26, no 8, 1829-1835 p.
Keyword [en]
impaired kidney function, denosumab, fractures, bone mineral density
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-157250DOI: 10.1002/jbmr.403ISI: 000293382600018OAI: oai:DiVA.org:uu-157250DiVA: diva2:436839
Available from: 2011-08-25 Created: 2011-08-22 Last updated: 2011-08-25Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text
By organisation
Department of Medical Sciences
In the same journal
Journal of Bone and Mineral Research
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 158 hits
ReferencesLink to record
Permanent link

Direct link